Concourse Financial Group Securities’s Autolus Therapeutics AUTL Stock Holding History

Concourse Financial Group Securities’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,000	Closed	-$4.21K	–	2168
2021 Q4	$5K	Hold	1,000	–	–	﹤0.01%	2022
2021 Q3	$7K	Hold	1,000	–	–	﹤0.01%	1968
2021 Q2	$7K	Hold	1,000	–	–	﹤0.01%	1956
2021 Q1	$6K	Hold	1,000	–	–	﹤0.01%	1907
2020 Q4	$9K	Sell	1,000 -500	-33%	-$5.33K	﹤0.01%	1709
2020 Q3	$17K	Buy	+1,500	New	+$21.8K	﹤0.01%	1409

Other funds holding AUTL

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Concourse Financial Group Securities's AUTL Position: Q1 2022 in Review

Concourse Financial Group Securities sold out of Autolus Therapeutics (AUTL) in Q1 2022, closing a stake of 1,000 shares — an estimated $4.21K sold.

Concourse Financial Group Securities first reported a position in AUTL in Q3 2020 and held it in 6 quarters. The position peaked at $17K in Q3 2020. 67 funds tracked by Wall St. Rank hold AUTL as of Q1 2022.

Concourse Financial Group Securities reported no remaining Autolus Therapeutics position as of Q1 2022 after selling out during the quarter.
Concourse Financial Group Securities sold 1,000 Autolus Therapeutics shares in Q1 2022, an estimated $4.21K.
Concourse Financial Group Securities first reported a position in Autolus Therapeutics in Q3 2020 and held it in 6 quarters.
Concourse Financial Group Securities's Autolus Therapeutics position peaked at $17K in Q3 2020.
67 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2022.

Based on Concourse Financial Group Securities's 13F filing for Q1 2022, filed 9 May 2022.